TCA
BCAB icon

Transcend Capital Advisors’s BioAtla BCAB Stock Holding History

Transcend Capital Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$17.6K – 575
2024
Q3 		$17.6K Buy
+200
New +$16.8K ﹤0.01% 615
2023
Q3 		– Sell
-980
Closed -$147K – 493
2023
Q2 		$147K Buy
+980
New +$169K 0.01% 466

Other funds holding BCAB

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Transcend Capital Advisors's BCAB Position: Q4 2024 in Review

Transcend Capital Advisors sold out of BioAtla (BCAB) in Q4 2024, closing a stake of 200 shares — an estimated $17.6K sold.

Transcend Capital Advisors first reported a position in BCAB in Q2 2023 and held it in 2 quarters. The position peaked at $147K in Q2 2023. 67 funds tracked by Wall St. Rank hold BCAB as of Q4 2024.

  • Transcend Capital Advisors reported no remaining BioAtla position as of Q4 2024 after selling out during the quarter.
  • Transcend Capital Advisors sold 200 BioAtla shares in Q4 2024, an estimated $17.6K.
  • Transcend Capital Advisors first reported a position in BioAtla in Q2 2023 and held it in 2 quarters.
  • Transcend Capital Advisors's BioAtla position peaked at $147K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held BioAtla as of Q4 2024.

Based on Transcend Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.